Similar effects are seen due to elevated levels of the oncometabolite D-2-hydroxyglutarate in gliomas with activating variants of the IDH1 and IDH2 genes encoding the isocitrate dehydrogenase enzymes [19, 39]. This evidence concerns the gene IDH3A and central nervous system cancer.